Differential expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines

Authors

  • A. R. M. Lobba,

    1. Biochemistry Department, Chemistry Institute, Cell and Molecular Therapy Center (NUCEL), University of São Paulo, 05508-000 São Paulo, Brazil
    Search for more papers by this author
  • M. F. Forni,

    1. Biochemistry Department, Chemistry Institute, Cell and Molecular Therapy Center (NUCEL), University of São Paulo, 05508-000 São Paulo, Brazil
    Search for more papers by this author
  • A. C. O Carreira,

    1. Biochemistry Department, Chemistry Institute, Cell and Molecular Therapy Center (NUCEL), University of São Paulo, 05508-000 São Paulo, Brazil
    Search for more papers by this author
  • M. C. Sogayar

    Corresponding author
    1. Biochemistry Department, Chemistry Institute, Cell and Molecular Therapy Center (NUCEL), University of São Paulo, 05508-000 São Paulo, Brazil
    • Chemistry Institute, University of São Paulo, Av. Prof. Lineu Prestes, 748, Bloco 9S São Paulo, 05508-000 SP, Brazil
    Search for more papers by this author

Abstract

The recently emerged concept of cancer stem cell (CSC) has led to a new hypothesis on the basis for tumor progression. Basically, the CSC theory hypothesizes the presence of a hierarchically organized and relatively rare cell population, which is responsible for tumor initiation, self-renewal, and maintenance, in addition to accumulation of mutation and resistance to chemotherapy. CSCs have recently been described in breast cancer. Different genetic markers have been used to isolate breast CSCs, none of which have been correlated with the tumorigenicity or metastatic potential of the cells, limiting their precise characterization and clinical application in the development of therapeutic protocols. Here, we sought for subpopulations of CSCs by analyzing 10 judiciously chosen stem cell markers in a normal breast cell line (MCF10-A) and in four human breast cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-435, and Hs578-T) displaying different degrees of metastatic and invasiveness potential. We were able to identify two markers, which are differentially expressed in nontumorigenic versus tumor cells. The CD90 marker was highly expressed in the malignant cell lines. Interestingly, the CD14 molecule displayed higher expression levels in the nontumorigenic cell line. Therefore, we demonstrated that these two markers, which are more commonly used to isolate and characterize stem cells, are differentially expressed in breast tumor cells, when compared with nontumorigenic breast cells. © 2012 International Society for Advancement of Cytometry

Ancillary